The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Michael W. N. Deininger

Division of Hematology & Oncology

OHSU Cancer Institute

Portland

OR 97239-3098

USA

[email]@ohsu.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hematology & Oncology, OHSU Cancer Institute, Portland, OR 97239-3098, USA. 2008
  • Oregon Health & Science University, Portland, Oregon 97239, USA. 2007 - 2008
  • Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, L592, 3181 Southwest Sam Jackson Park Road, Portland, USA. 2007 - 2008
  • OHSU Cancer Institute, Center for Hematologic Malignancies, Portland, OR 97239, USA. 2005 - 2006
  • BMT/Leukemia Center, Oregon Health and Science University, Mailcode L592, 3181 S.W. Sam Jackson Park Road, USA. 2003 - 2005

References

  1. Milestones and monitoring in patients with CML treated with imatinib. Deininger, M.W. Hematology. Am. Soc. Hematol. Educ. Program (2008) [Pubmed]
  2. Resistance and relapse with imatinib in CML: causes and consequences. Deininger, M. J. Natl. Compr. Canc. Netw (2008) [Pubmed]
  3. Nilotinib. Deininger, M.W. Clin. Cancer Res. (2008) [Pubmed]
  4. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Deininger, M.W., Cortes, J., Paquette, R., Park, B., Hochhaus, A., Baccarani, M., Stone, R., Fischer, T., Kantarjian, H., Niederwieser, D., Gambacorti-Passerini, C., So, C., Gathmann, I., Goldman, J.M., Smith, D., Druker, B.J., Guilhot, F. Cancer (2007) [Pubmed]
  5. Optimizing therapy of chronic myeloid leukemia. Deininger, M.W. Exp. Hematol. (2007) [Pubmed]
  6. The effect of prior exposure to imatinib on transplant-related mortality. Deininger, M., Schleuning, M., Greinix, H., Sayer, H.G., Fischer, T., Martinez, J., Maziarz, R., Olavarria, E., Verdonck, L., Schaefer, K., Boqué, C., Faber, E., Nagler, A., Pogliani, E., Russell, N., Volin, L., Schanz, U., Doelken, G., Kiehl, M., Fauser, A., Druker, B., Sureda, A., Iacobelli, S., Brand, R., Krahl, R., Lange, T., Hochhaus, A., Gratwohl, A., Kolb, H., Niederwieser, D. Haematologica (2006) [Pubmed]
  7. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Deininger, M., Buchdunger, E., Druker, B.J. Blood (2005) [Pubmed]
  8. Management of early stage disease. Deininger, M.W. Hematology. Am. Soc. Hematol. Educ. Program (2005) [Pubmed]
  9. Resistance to imatinib: mechanisms and management. Deininger, M. J. Natl. Compr. Canc. Netw (2005) [Pubmed]
  10. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. Deininger, M.W. J. Cancer Res. Clin. Oncol. (2004) [Pubmed]
  11. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Deininger, M.W., Druker, B.J. Pharmacol. Rev. (2003) [Pubmed]
 
WikiGenes - Universities